This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

GSK-Pfizer deal prompts New Zealand regulator's preliminary remarks

( March 20, 2019, 02:27 GMT | Official Statement) -- MLex Summary: The impact of GlaxoSmithKline's plans to acquire Pfizer's consumer healthcare business will be vetted by New Zealand's competition regulator. The New Zealand Commerce Commission will review the possible affect of the deal on price increases in the consumer-health market. In a statement of issues released today, the Commerce Commission said that it needs to consider whether the deal could lead to conglomerate effects, allowing GSK to "tie certain products together." The Commerce Commission is expected to announce a decision on the deal on May 7.The full statement follows, and the statement of preliminary issues is attached: ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections